Insulet (NASDAQ:PODD) Rating Increased to Hold at UBS Group

UBS Group upgraded shares of Insulet (NASDAQ:PODD) to a hold rating in a research note published on Tuesday morning,Zacks.com reports.

Several other brokerages have also commented on PODD. TD Cowen dropped their price target on shares of Insulet from $379.00 to $294.00 and set a “hold” rating on the stock in a research note on Monday, June 1st. Wall Street Zen downgraded shares of Insulet from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Sanford C. Bernstein lowered their target price on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Stifel Nicolaus dropped their target price on shares of Insulet from $250.00 to $225.00 and set a “buy” rating on the stock in a research report on Friday, July 10th. Finally, Raymond James Financial set a $216.00 price target on shares of Insulet in a research note on Monday, June 8th. Twenty-one investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Insulet presently has an average rating of “Moderate Buy” and a consensus target price of $233.38.

Insulet Stock Up 1.5%

Shares of NASDAQ PODD opened at $167.47 on Tuesday. The business has a 50-day moving average of $154.59 and a two-hundred day moving average of $200.20. The company has a market capitalization of $11.60 billion, a price-to-earnings ratio of 38.95, a price-to-earnings-growth ratio of 1.15 and a beta of 1.11. Insulet has a 1 year low of $138.79 and a 1 year high of $354.88. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the prior year, the business posted $1.02 EPS. The business’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, analysts forecast that Insulet will post 6.45 earnings per share for the current fiscal year.

Insider Activity at Insulet

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.36% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC boosted its stake in shares of Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new position in Insulet in the 4th quarter valued at about $26,000. DV Equities LLC acquired a new position in Insulet in the 4th quarter valued at about $28,000. Elyxium Wealth LLC purchased a new stake in Insulet during the 4th quarter valued at approximately $28,000. Finally, Mcguire Capital Advisors Inc. acquired a new stake in Insulet during the 4th quarter worth approximately $29,000.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Negative Sentiment: Multiple law firms are promoting a securities-fraud class action against Insulet and certain senior executives. The lawsuits allege that the company misrepresented the safety of its Omnipod products and failed to disclose manufacturing deficiencies. These are allegations, not established findings. PODD Class Reminder article
• Negative Sentiment: The litigation follows a stock decline of more than 6% reportedly triggered by disclosures involving the safety of Insulet’s Omnipod products. If the claims gain traction, potential costs could include legal expenses, settlements, damages, regulatory scrutiny and reputational harm. PODD Shareholder Alert article
• Negative Sentiment: One shareholder alert highlights an alleged $3.7 million sale of Insulet stock by executive Eric Benjamin before two medical-device corrections. Plaintiffs may use the timing to support claims of inadequate disclosure, although the allegations have not been proven. Executive accountability shareholder alert
• Neutral Sentiment: The federal class action is pending in the District of Massachusetts, with proposed class periods generally covering purchases from February 21 or May 21, 2025 through May 26, 2026. Investors have until August 31, 2026 to seek appointment as lead plaintiff. The deadline is procedural and does not determine Insulet’s liability. Pomerantz class action article

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.